-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that on November 19, Genting Xinyao (01952.HK) announced that the VIS-101 phase IIb Ascend clinical study to treat wet age-related macular degeneration (wet AMD) had completed the first patient administration.

智通财经·11/19/2026 07:09:12
语音播报
The Zhitong Finance App learned that on November 19, Genting Xinyao (01952.HK) announced that the VIS-101 phase IIb Ascend clinical study to treat wet age-related macular degeneration (wet AMD) had completed the first patient administration.